Droperidol and QTc Interval Changes in ED Patients
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorCHRISTUS Health
About this trial
Objectives To assess the association of low-dose Droperidol administration in the emergency department with changes in the QTc interval.
Hypothesis Our study is designed to test the null hypothesis that there will be no clinically significant change in QTc interval after administration of 2.5mg of IV Droperidol during an emergency department visit.
Eligibility criteria
Qualifiers
ED patients ages 18 years or older in a cardiovascular-monitored bed who have both an ECG and a 2.5 mg dose of IV droperidol ordered by their treating physician will be eligible for inclusion.
Disqualifiers
Refusal to provide consent.
Administration of droperidol before the first ECG is performed.
Inability to complete the consent form and questionnaire due to clinical instability, severe pain, or disorientation as determined by a study physician.
Trial design
Treatments tested in this trial
- Droperidol injection
Treatment groups
No treatment groups listed
Sponsors and collaborators
Source ClinicalTrials.gov